CA2666538A1 - Utilisation de la citrulline pour le traitement des etats de denutrition - Google Patents

Utilisation de la citrulline pour le traitement des etats de denutrition Download PDF

Info

Publication number
CA2666538A1
CA2666538A1 CA002666538A CA2666538A CA2666538A1 CA 2666538 A1 CA2666538 A1 CA 2666538A1 CA 002666538 A CA002666538 A CA 002666538A CA 2666538 A CA2666538 A CA 2666538A CA 2666538 A1 CA2666538 A1 CA 2666538A1
Authority
CA
Canada
Prior art keywords
citrulline
intestinal
protein
pathologies
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002666538A
Other languages
English (en)
French (fr)
Inventor
Christophe Moinard
Marion Jourdan
Stephane Walrand
Luc Cynober
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Paris Descartes
Biocodex SAS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2666538A1 publication Critical patent/CA2666538A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002666538A 2006-10-17 2007-08-29 Utilisation de la citrulline pour le traitement des etats de denutrition Abandoned CA2666538A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR06/09077 2006-10-17
FR0609077A FR2907011B1 (fr) 2006-10-17 2006-10-17 Utilisation de la citrulline pour le traitement des etats de denutrition
PCT/FR2007/001407 WO2008049984A2 (fr) 2006-10-17 2007-08-29 Utilisation de la citrulline pour le traitement des etats de denutrition

Publications (1)

Publication Number Publication Date
CA2666538A1 true CA2666538A1 (fr) 2008-05-02

Family

ID=37888135

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002666538A Abandoned CA2666538A1 (fr) 2006-10-17 2007-08-29 Utilisation de la citrulline pour le traitement des etats de denutrition

Country Status (8)

Country Link
US (1) US20100298437A1 (enExample)
EP (1) EP2081564B1 (enExample)
JP (1) JP2010506887A (enExample)
CN (1) CN101605538A (enExample)
CA (1) CA2666538A1 (enExample)
FR (1) FR2907011B1 (enExample)
IL (1) IL198182A0 (enExample)
WO (1) WO2008049984A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2913885B1 (fr) * 2007-03-22 2012-07-20 Univ Paris Descartes Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
DE102007016715A1 (de) * 2007-04-04 2008-10-09 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
FR2970414B1 (fr) 2011-01-14 2013-03-22 Univ Paris Descartes Action preventive de la citrulline sur le developpement spontane des tumeurs
EP3021690B1 (en) 2013-06-10 2017-05-17 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
FR3009963B1 (fr) 2013-09-03 2017-03-03 Biolis Composition de lutte contre les troubles de la locomotion
EP2875736B1 (en) 2013-11-26 2016-07-27 Citrage N-Carbamoylputrescine to enhance muscle protein synthesis
WO2015137387A1 (ja) * 2014-03-11 2015-09-17 協和発酵バイオ株式会社 筋肉増強剤
CN104263550A (zh) * 2014-09-11 2015-01-07 滁州斯迈特复合材料有限公司 化妆液玻璃瓶清洁剂
ES2798772T3 (es) * 2015-09-04 2020-12-14 Univ Tsukuba Composición para el desarrollo muscular y método para desarrollar músculo
KR102396603B1 (ko) 2015-09-16 2022-05-11 원광대학교산학협력단 시트룰린을 유효성분으로 함유하는 간 기능 개선용 조성물
CN108473384A (zh) 2015-10-27 2018-08-31 细胞酶动物营养品公司 动物营养成分及相关方法
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
AU2018415594B2 (en) 2018-03-27 2024-10-10 N.V. Nutricia Insulin control in overweight or obese adult during life time intervention
CN118248029A (zh) * 2024-03-21 2024-06-25 江南大学 一种月球环境下的仿生结肠发酵系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6305M (enExample) * 1966-12-15 1968-09-16
FR6304M (enExample) * 1966-12-15 1968-09-16
FR6306M (enExample) * 1966-12-15 1968-09-16
US5189025A (en) * 1988-12-09 1993-02-23 Board Of Regenets, The University Of Texas System Methods for the treatment of malignant disease in patients using citrulline containing amino acid solutions
US4988724A (en) * 1988-12-09 1991-01-29 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
FR2691359B1 (fr) * 1992-05-20 1995-06-23 Krempf Michel Nouvelle application therapeutique du malate de 1-citrulline.
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
FR2857262B1 (fr) * 2003-07-08 2007-10-05 Biocodex Lab Utilisation de la citrulline dans le cadre de l'insuffisance intestinale

Also Published As

Publication number Publication date
EP2081564A2 (fr) 2009-07-29
US20100298437A1 (en) 2010-11-25
EP2081564B1 (fr) 2014-01-01
IL198182A0 (en) 2009-12-24
FR2907011A1 (fr) 2008-04-18
CN101605538A (zh) 2009-12-16
WO2008049984A2 (fr) 2008-05-02
FR2907011B1 (fr) 2010-05-14
JP2010506887A (ja) 2010-03-04
WO2008049984A3 (fr) 2008-06-19

Similar Documents

Publication Publication Date Title
EP2081564B1 (fr) Utilisation de la citrulline pour le traitement des etats de denutrition
TWI775921B (zh) 用於治療和高血氨症或肌肉耗損中之一者或兩者相關之肝疾病及失調之組合物及方法
Grimble Adverse gastrointestinal effects of arginine and related amino acids
EP3173079B1 (en) Materials and methods for improving gastrointestinal function
CA2071971C (en) The use of arginine as an immunostimulator
CN111479580A (zh) 采用自噬诱发剂和高蛋白质的组合来诱发自噬的组合物和方法
CA2689608A1 (fr) Utilisation de la citrulline pour la prevention de l`augmentation de la carbonylation des proteines et du traitement des pathologies qui en decoulent
FR2797767A1 (fr) Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances
Ajibade et al. L-arginine and lisinopril supplementation protects against sodium fluoride–induced nephrotoxicity and hypertension by suppressing mineralocorticoid receptor and angiotensin-converting enzyme 3 activity
EP0655244B2 (fr) Composition à base d'acides aminés pour le traitement d'infections
FR2556593A1 (fr) Composition nutritive contenant de l'acide alpha-cetoisocaproique, de la leucine et des acides amines essentiels et non essentiels
EP1495755B1 (fr) Utilisation de la citrulline dans la fabrication d'un médicament pour le traitement de l'insuffisance intestinale liée au vieillissement ou à une irradiation
EP1648431B1 (fr) Utilisation d'une composition pauvre en polyamines pour la realisation d'un aliment therapeutique humain
EP1807069B1 (en) Methods for regulating weight and size of animals with glycine
CN110621304A (zh) 活性成分的组合、包含该组合的组合物及其在治疗肌肉减少症中的用途
TWI878045B (zh) 雞肉水解物用於治療或預防藥物性肝臟損傷之用途
WO2006125847A1 (es) Obtención y propiedades antihipertensivas de péptidos derivados de proteínas de clara de huevo
RU2223670C1 (ru) Биологически активная добавка к пище
Farges et al. Oral administration of a glutamine-enriched diet before or after endotoxin challenge in aged rats has limited effects
EP2398560A1 (en) Methods for treating lipomas and liposarcomas
JPH02121928A (ja) Ｌ−チロシンのジペプチドを含有する栄養輸液組成物
FR2643266A1 (fr) Solute d'apport d'acides amines pour alimentation parenterale
RU2324703C1 (ru) Пептидное соединение, стимулирующее функцию половой системы, фармацевтическая композиция на его основе и способ ее применения
OA20063A (en) Amino acid compositions for the treatment of liver disease.
Maher et al. Aspartame Administration Decreases the Entry of α-Methyldopa into the Brain of Rats

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150402